Hims & Hers Health shares came under pressure after the US Federal Trade Commission announced legal action against the telehealth company over alleged privacy, billing and subscription-cancellation practices.
The lawsuit, filed with Los Angeles County and the state of Utah, alleges that Hims & Hers shared sensitive consumer health information with advertising platforms despite assuring users that their data would remain private. The FTC also claims the company charged some customers before they had received a consultation with a healthcare provider and made subscriptions unnecessarily difficult to cancel.
The allegations have not yet been proven in court. Nevertheless, they introduce a significant new source of regulatory uncertainty for a company whose business depends heavily on consumer trust, digital marketing and recurring subscriptions.
For HIMS stock investors, the central question is whether the case results in financial penalties and manageable compliance changes or forces a broader restructuring of the company’s customer-acquisition and subscription model.
What the FTC Alleges Against Hims & Hers
The FTC’s planned complaint focuses on three main areas: data privacy, prescription billing and subscription cancellations.
According to the agency, Hims & Hers allegedly transmitted sensitive information generated through consumers’ interactions with its website to advertising companies including Meta Platforms and Snap. The alleged transfers occurred through tracking technologies embedded in the company’s digital services.
Health-related data can be particularly sensitive because Hims & Hers offers services involving weight management, sexual health, hair loss and mental-health treatments. Consumers may reasonably expect information connected with these conditions to receive a high level of protection.
The FTC also alleges that Hims & Hers began charging customers for prescriptions before they had a meaningful opportunity to meet with a healthcare provider. In some cases, the agency claims customers were charged shortly after submitting an online intake form.
A third allegation involves cancellation procedures. The FTC says the company made it difficult for users to end recurring subscriptions, an issue that can attract regulatory scrutiny when consumers continue being billed after attempting to cancel.
The lawsuit follows an earlier FTC investigation into Hims & Hers’ advertising and cancellation practices. That investigation became public in August 2025, when reports indicated that the agency had been examining customer complaints and had previously requested information from the company.
Why the Privacy Allegations Matter
The privacy component may be the most damaging part of the case from a reputational perspective.
Hims & Hers operates a digital healthcare platform through which customers provide personal details before receiving treatment recommendations or prescriptions. The success of that model depends on users feeling comfortable sharing information they might not discuss openly in other settings.
The FTC alleges that some of this information was transmitted to advertising platforms even though consumers had been given assurances about privacy.
When a digital health company uses advertising trackers, the regulatory issue is not necessarily limited to whether a consumer’s name or medical record was shared. Data concerning page visits, questionnaire responses or treatment interests may still reveal information about a person’s health concerns.
A loss of trust could affect conversion rates and customer retention. Potential users may be less willing to complete online assessments when they believe their activity could be used for advertising purposes.
Hims & Hers may also need to remove or redesign tracking systems, revise consent procedures and limit how customer data is used for marketing. Those changes could make digital advertising less efficient and increase the cost of acquiring each new subscriber.
Subscription Billing Is Central to the Business Model
The lawsuit also challenges practices connected with Hims & Hers’ recurring-revenue model.
The company offers memberships and treatment plans that automatically renew, creating predictable revenue when customers remain on the platform. Its public website currently describes membership-based weight-loss services that renew monthly and are billed separately from medication.
Subscription models can be financially attractive because companies do not need to win the same customer again for every purchase. However, regulators expect businesses to disclose recurring charges clearly, obtain informed consent and provide straightforward cancellation procedures.
The FTC alleges that Hims & Hers charged some consumers before a provider consultation had occurred and made cancellation unnecessarily difficult.
When the court agrees with those claims, the company could be required to alter how quickly it processes payments, provide clearer disclosures or create easier cancellation tools.
Those changes could increase cancellations and reduce the lifetime value of each subscriber. They could also delay the point at which Hims & Hers recognizes revenue from new customers.
The financial effect will depend on how many users were affected and whether the alleged practices were isolated or widespread.
What the Lawsuit Could Mean for HIMS Stock
The immediate share-price decline reflects uncertainty rather than a confirmed financial loss.
Regulatory cases can affect a stock through several channels. The company may incur legal expenses, potential penalties and compliance costs. Management attention may also be diverted from growth initiatives while the litigation continues.
The larger risk is that the case changes the economics of Hims & Hers’ customer-acquisition model.
The company relies heavily on digital advertising to reach consumers searching for treatments that can be delivered through telehealth. Restrictions on tracking and data use could make advertising campaigns less targeted and potentially more expensive.
Simpler cancellation processes could also increase customer churn. Churn measures the percentage of subscribers who stop using a service during a particular period. Higher churn forces a subscription company to acquire more new customers simply to maintain its revenue base.
However, the lawsuit does not automatically invalidate the company’s broader growth strategy. Hims & Hers continues to operate across several healthcare categories and markets a wide range of prescription and non-prescription treatments through its platform.
The investment outcome will depend on whether the company can address the allegations without materially weakening customer growth or profitability.
Regulatory Pressure Is Already a Major Investor Concern
The FTC case arrives while Hims & Hers is already facing scrutiny from other regulators and private litigants.
The US Food and Drug Administration issued a warning letter in September 2025 concerning claims connected with compounded semaglutide products marketed through the Hers platform. The FDA said certain claims were false or misleading and noted that compounded medicines are not reviewed in the same way as FDA-approved drugs.
The company has also faced disputes and litigation related to compounded weight-loss treatments and its former commercial relationship with Novo Nordisk.
These matters are legally separate from the FTC lawsuit, but together they increase the regulatory risk attached to HIMS stock.
Investors may apply a lower valuation to the shares when they believe future growth depends on business practices that could be restricted or altered by regulators.
The combined scrutiny also makes clear communication important. Management will need to explain how privacy safeguards, clinical consultations, billing procedures and pharmaceutical compliance are being strengthened.
What Hims & Hers Investors Should Watch Next
The first major development will be the formal legal response from Hims & Hers.
Investors should look for whether the company disputes the factual allegations, seeks a negotiated settlement or announces immediate operational changes.
Any proposed financial penalty will be important, but the required business-practice changes may have a larger long-term effect. Restrictions on advertising data, revised billing timing and easier cancellation procedures could influence revenue growth even when the direct monetary settlement is relatively modest.
Future earnings reports should be examined for changes in subscriber growth, marketing efficiency and customer-retention costs.
Management may also disclose additional legal reserves. A legal reserve is an accounting estimate for losses the company considers probable and reasonably measurable.
The lawsuit does not determine the long-term value of Hims & Hers by itself. It does, however, raise important questions about whether the company’s digital subscription model can continue operating with the same economics under tighter privacy and consumer-protection requirements.
FAQ
Why did Hims & Hers stock fall?
HIMS stock declined after the FTC announced a lawsuit alleging that the company shared sensitive health information with advertisers and used deceptive billing and subscription-cancellation practices.
What data does the FTC say was shared?
The agency alleges that information connected with users’ interactions on Hims & Hers’ website was transmitted through tracking technologies to advertising companies including Meta and Snap.
Did Hims & Hers charge customers before consultations?
The FTC alleges that some users were charged for prescriptions shortly after completing an intake form and before receiving an adequate consultation with a healthcare provider.
Has Hims & Hers been found liable?
No. The claims are allegations contained in a lawsuit and must still be resolved through the legal process.
What is the biggest risk for HIMS investors?
The main risk is that privacy and subscription reforms increase customer-acquisition costs, raise cancellations and weaken the profitability of the company’s recurring-revenue model.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Always conduct your own research before making any investment decisions.
